Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus

Published:2019-04-18 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Madsen Kasper S¹,Kähler Pernille²,Kähler Lise Katrine Aronsen¹,Madsbad Sten³,Gnesin Filip⁴,Metzendorf Maria-Inti⁵,Richter Bernd⁵,Hemmingsen Bianca⁵

Affiliation:

1. University of Copenhagen; Faculty of Health and Medical Sciences; Blegdamsvej 3B Copenhagen N Denmark 2200

2. Faculty of Health and Medical Sciences; Copenhagen Medical University; Blegdamsvej 3 Copenhagen Denmark 2100Ø

3. Hvidovre Hospital, University of Copenhagen; Department of Endocrinology; Hvidovre Denmark

4. Department 7652, Rigshospitalet; Department of Endocrinology, Diabetes and Metabolism; Blegdamsvej 9 Copenhagen Denmark DK-2100

5. Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf; Cochrane Metabolic and Endocrine Disorders Group; Moorenstr. 5 Düsseldorf Germany 40225

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012368.pub2/epdf/full

Reference374 articles.

1. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials;Ahrén;Diabetes Research and Clinical Practice,2017

2. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin;Ahrén;Diabetes Care,2014

3. Ahrén B Stewart M Cirkel D Yang F Perry C Johnson S HARMONY 3: 104 week (wk) efficacy of albiglutide (albi) compared to sitagliptin (sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (met) 73rd Scientific Sessions. American Diabetes Assosciation. 2013 June 21-25; Chicago (IL) American Diabetes Assosciation 2013

4. Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY;Doggrell;Expert Review of Endocrinology and Metabolism,2015

5. Cardiovascular safety of albiglutide in the HARMONY Programme: a meta-analysis;Fisher;Lancet Diabetes & Endocrinology,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years;Diabetes Research and Clinical Practice;2024-08

2. The Coming Age of Antisense Oligos for the Treatment of Hepatic Ischemia/Reperfusion (IRI) and Other Liver Disorders: Role of Oxidative Stress and Potential Antioxidant Effect;Antioxidants;2024-05-31

3. The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis;American Journal of Physiology-Cell Physiology;2024-05-01

4. Therapie des Typ-2-Diabetes;Die Diabetologie;2024-01-30

5. An update on the bioactivities and health benefits of two plant-derived lignans, phyllanthin and hypophyllanthin;Advances in Traditional Medicine;2024-01-27